Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy treatment has no fixed end date built into the licence — for most adults it continues for as long as the medicine is clinically appropriate and producing benefit. The NICE guidance for semaglutide on the NHS caps it at two years within specialist services, but private treatment through a regulated prescriber is reassessed individually at every repeat. That distinction matters if you are weighing up your options. It can feel unsettling to start a medicine without knowing exactly how long you will need it; that uncertainty is completely understandable, and this page works through the timeline step by step, from the titration phase through to maintenance and the question of stopping. Wegovy (semaglutide) is a prescription-only medicine, so every stage of duration (starting, continuing, and any decision to stop) is a clinical decision made by your prescriber, not a fixed schedule you follow on your own. The NHS semaglutide medicines page gives a reliable overview of what the treatment involves.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Treatment begins at 0.25 mg once weekly. This starting dose is not intended to produce weight loss — its job is to let your body adjust gradually, reducing the chance of nausea or other gastrointestinal discomfort that can come with the medicine. After four weeks the dose typically steps to 0.5 mg, then 1.0 mg, then 1.7 mg, with each increase roughly a month apart. Most people reach the 2.4 mg maintenance dose around week 16 or 17. Some find they need an extra four weeks at a particular level before moving up, that is not a setback, just a sign that a slower pace suits them, and it is always a conversation to have with your prescriber rather than a self-managed decision.
During this phase you may notice appetite changes and some early weight shift, though the larger changes tend to come once you settle on the maintenance dose. The factors that affect how quickly Wegovy starts working are worth reading alongside this, because the titration window and the onset of meaningful results are related but not identical.
Once you are on 2.4 mg, the treatment enters its most active period. The STEP 1 clinical trial (68 weeks, 2.4 mg versus placebo, published in the New England Journal of Medicine) recorded around 15% average body-weight reduction. Most of that loss accumulated during the first year of treatment. Weight reduction tends to slow and eventually plateau as the body reaches a new equilibrium; that plateau is expected and does not mean the medicine has stopped working.
Privately prescribed Wegovy through a GPhC-registered pharmacy like ours has no automatic two-year ceiling. Your prescriber reviews the clinical picture at every repeat: whether results are continuing, whether side effects are manageable, and whether the balance of benefit still makes sense for you. The review at six months on maintenance dose matters especially. If weight loss has not reached 5% by that point, the guidance from NICE's appraisal of semaglutide (TA875) is to reconsider continuing, and an honest prescriber will have that conversation with you directly.
Curious how the speed of loss varies from person to person? The page on how fast Wegovy weight loss typically is goes into that in more detail.
What happens when treatment ends is one of the most common questions prescribers hear. The evidence is clear that stopping semaglutide generally leads to partial weight regain over time, because the medicine was managing an ongoing physiological process rather than curing an underlying condition. For many people that means treatment is genuinely long-term, continued for years rather than months, with regular clinical reassessment.
If you and your prescriber decide to stop, the approach is typically a conversation about lifestyle consolidation and whether alternative support is appropriate. There is no standard tapering schedule required under the licence; the prescriber's judgement applies. For context on how long the medicine itself remains active in the body after the last dose, the clearance timeline for semaglutide explains what to expect physiologically.
Planning alongside treatment matters too. Questions about realistic timelines for weight loss on Wegovy are best framed against the full treatment arc rather than the first few weeks alone.
On the NHS, NICE's recommendation (TA875) states that Wegovy should be used for a maximum of two years, within a specialist weight management service that includes multidisciplinary support. That ceiling reflects NHS resource considerations as much as clinical ones. Privately, the picture is different: duration is determined by clinical need, not a policy cap, as long as treatment continues to be appropriate and safe for you.
For an overview of what Wegovy treatment involves from start to finish (including eligibility and the private versus NHS routes) the Wegovy treatment guide covers the full picture. If cost across a longer treatment period is something you are thinking through, the Wegovy cost and pricing page sets out what private treatment typically involves financially, without hiding the real numbers. A free consultation with our prescribers is the right starting point if you want a view on your own timeline specifically. Every patient's situation is reviewed individually, a free consultation is always the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.